2019
DOI: 10.21037/tcr.2019.05.12
|View full text |Cite
|
Sign up to set email alerts
|

Rare epithelial breast cancer: surgery and adjuvant therapy

Abstract: Breast cancer is a heterogenous disease, exhibiting a wide range of morphological phenotypes shaping its prognosis and clinical course. However, optimal management of rarer breast cancer subtypes is often undefined and controversial in literature due to the lack of large studies and randomised trials. This review aims to discuss the treatment of 13 rare epithelial subtypes, focussing on surgery and adjuvant therapies.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

2
6
0

Year Published

2020
2020
2024
2024

Publication Types

Select...
4
1

Relationship

0
5

Authors

Journals

citations
Cited by 5 publications
(8 citation statements)
references
References 119 publications
(160 reference statements)
2
6
0
Order By: Relevance
“…There were only 4 patients with HER2 + in our study, and most of patients were HR + / HER2 -. The results of subtype were consistent with previous studies 6, [26][27] . The 66-month overall survival (OS) rate in NEC was 44.5% and 56.3%, which was worse than IDC, respectively.…”
Section: Discussionsupporting
confidence: 93%
See 2 more Smart Citations
“…There were only 4 patients with HER2 + in our study, and most of patients were HR + / HER2 -. The results of subtype were consistent with previous studies 6, [26][27] . The 66-month overall survival (OS) rate in NEC was 44.5% and 56.3%, which was worse than IDC, respectively.…”
Section: Discussionsupporting
confidence: 93%
“…Patients with NEC can bene t from chemotherapy (HR = 8.468, p = 0.000) which is the only factor that clinicians can control. At present, doctors determine whether patients need chemotherapy and chemotherapy regimens according to the patient's age, molecular typing, stage, 21 gene and so on 26,28 . We suggest NEC patients all receive chemotherapy if it is necessary.…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…Patients diagnosed with small cell carcinoma had higher rates of HR–/HER2– compared with the other subgroups (neuroendocrine tumor with well-differentiated, large cell neuroendocrine carcinoma, and carcinoma with neuroendocrine differentiation). Overall, patients with breast NEC had a higher HR+/HER2- ratio than patients with breast IDC, which was similar to previous findings [ 6 , 26 , 27 ]. Patients with breast NEC and IDC had different treatment choices.…”
Section: Discussionsupporting
confidence: 91%
“…Patients diagnosed with NEBC with positive hormone receptors are candidates to receive adjuvant endocrine therapy. As observed in many cases of NETs [43], adjuvant endocrine therapy is supposed to increase survival, but evidence of efficacy needs clinical trials and is to date only anedoctal [44].…”
Section: Chemotherapymentioning
confidence: 99%